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Abstract: Background: Sexually transmitted gonorrhea, caused by the Gram-negative diplococcus
Neisseria gonorrhoeae, continues to be a serious global health challenge despite efforts to eradicate
it. Multidrug resistance among clinical N. gonorrhoeae isolates has limited treatment options, and
attempts to develop vaccines have not been successful. Methods: A search of published literature
was conducted, and information extracted to provide an update on the status of therapeutics and
vaccine development for gonorrheal infection. Results: Recommended pharmacological treatment
for gonorrhea has changed multiple times due to increasing acquisition of resistance to existing
antibiotics by N. gonorrhoeae. Only broad-spectrum cephalosporin-based combination therapies
are currently recommended for treatment of uncomplicated urogenital and anorectal gonococcal
infections. With the reported emergence of ceftriaxone resistance, successful strategies addressing the
global burden of gonorrhea must include vaccination. Century-old efforts at developing an effective
vaccine against gonorrhea, leading to only four clinical trials, have not yielded any successful vaccine.
Conclusions: While it is important to continue to explore new drugs for the treatment of gonorrhea,
the historical trend of resistance acquisition suggests that any long-term strategy should include
vaccine development. Advanced technologies in proteomics and in silico approaches to vaccine
target identification may provide templates for future success.
Keywords: gonorrhea; Neisseria gonorrhoeae; multidrug resistance; ceftriaxone; azithromycin; proteomics-
driven vaccine antigen discovery; in silico approaches to vaccine antigen identification; vaccine development
1. Introduction
Gonorrhea, a sexually transmitted infectious disease caused by the bacterium Neisse-
ria gonorrhoeae (gonococcus), has remained an intractable global health problem despite
continuing efforts to curtail its health impacts. The public health challenge posed by gon-
orrhea stems primarily from the large number of asymptomatic infected individuals, the
ability of the gonococcus to undergo high levels of surface antigenic variation, and the
progressive emergence of antibiotic-resistant gonococcal strains to recommended empiric
monotherapies [1]. The World Health Organization (WHO) cited an increase in the number
of new and untreated cases globally due to therapeutic failures and the asymptomatic
nature of the disease [2]. According to the WHO, approximately 87 million people were
diagnosed with gonorrhea out of the 376 million globally reported cases of sexually trans-
mitted infections (STIs) that occurred among 15–49 year olds in 2016. Estimated global
prevalence of urogenital gonorrhea was higher among females (0.9%) compared to males
(0.7%) [3]. Additionally, the epidemiology of incident cases of gonorrhea varies widely by
geographical WHO region, with the highest prevalence in the African region (women 1.9%;
men 1.6%), the Americas (women 0.9%; men 0.8%), and the Western Pacific region (women
0.9%; men 0.7%), and the lowest prevalence in Europe (women 0.3%; men 0.3%) [3]. It is
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believed that these numbers likely underestimate the actual cases of gonorrhea globally [4].
Epidemiological STI surveillance and diagnostics are inadequate in most developing and
resource-limited countries, where actual infection numbers are difficult to estimate. Differ-
ences in socioeconomic conditions, cultural perceptions of STIs, and access to quality STI
education and prevention measures also likely contribute to this heterogeneity in country-
specific prevalence data [5]. In 2018, a total of 583,405 gonorrheal cases were reported in the
United States alone (i.e., a rate of 179.1 cases per 100,000 population), making gonorrhea
the second most commonly reported STI [6]. According to the U.S. Centers for Disease
Control and Prevention (CDC), the incidence of gonorrhea continues to rise annually [6].
Case reporting data indicated that the rate of U.S. gonococcal infections increased 5.0%
during the period 2017–2018 and increased 82.6% since 2009, when reported gonorrhea
cases declined to an historic low [6]. Regional, gender, and ethnicity disparities in rates of
reported gonorrhea cases are also observed in the U.S. Surveillance data collected by the
CDC revealed that the South had the highest rate of gonorrhea cases in 2018 (194.4 cases per
100,000 population) compared to the Northeast, which had the lowest rate (138.4 cases per
100,000 population) [6]. The rate of reported gonorrhea cases among males increased by a
higher amount compared to females (6.0% versus 3.6%, respectively) in 2018. Finally, 2018
rates of reported gonococcal infections were the highest among Blacks (548.9 cases/100,000),
American Indians/Alaska Natives (329.5 cases/100,000), Native Hawaiians/Other Pacific
Islanders (181.4 cases/100,000), and Hispanics (115.9 cases/100,000), while rates remained
the lowest among Whites (71.1 cases/100,000) and Asians (35.1 cases/100,000) [6]. U.S.
rates of gonorrhea are also likely underestimated due to incomplete reporting. Furthermore,
the majority of infected people are asymptomatic and constitute an important source of
infection transmission [1,7].
N. gonorrhoeae is a human-restricted pathogen that infects the lower genital tract,
pharynx, and rectum, with varying degrees of complication depending on the sex of the
patient. The predominant site of infection is the cervix in females and the anterior urethra
in males. Although gonorrhea is most commonly seen in young individuals 15–24 years
of age, it can be present in any sexually active individual [6]. Symptoms of gonorrhea
include cervical or urethral purulent discharge, discomfort, dysuria, urethritis, or cervicitis.
Untreated cervical infection may result in ascension of the gonococcus to the upper genital
tract and lead to serious reproductive health complications such as pelvic inflammatory
disease (PID), chronic pelvic pain, ectopic pregnancy, and tubal infertility [7,8]. Vertical
transmission is a significant concern for pregnant women infected with N. gonorrhoeae
and may lead to chorioamnionitis, septic abortion, premature rupture, preterm delivery,
and sight-threatening neonatal conjunctivitis [9]. In males, rare disease complications and
sequelae of untreated urethritis include penile edema, urethral stricture, epididymitis, or
prostatitis [10]. Untreated urogenital gonorrhea infrequently disseminates to extragenital
anatomic sites, causing septic arthritis, endocarditis, and skin manifestations in both
genders. Moreover, N. gonorrhoeae infection facilitates the acquisition and transmission of
other STIs, most notably HIV infection [11].
The lack of natural immunity in both symptomatic and asymptomatic patients has
impeded development of an effective anti-gonococcal vaccine. Strain-specific antibod-
ies directed against a number of gonococcal antigens (e.g., lipooligosaccharide [LOS],
pili, and outer membrane proteins [PorB, Opa]) have been detected in the sera, seminal
plasma, and cervical secretions of individuals infected with N. gonorrhoeae (reviewed in [7]).
However, these humoral immune responses to N. gonorrhoeae tend to be modest, with anti-
body production in infected individuals characterized as only slightly increased compared
to uninfected individuals and not protective against reinfection [12]. While in vitro evi-
dence exists for some anti-gonococcal antibodies promoting either complement-mediated
killing or opsonin-facilitated phagocytosis of the gonococcus [13,14], the potential role of
these antibodies in immunologic clearance of the pathogen from the host remains unclear.
The persistence of gonococcal infections and the common occurrence of reinfection are
consistent with evidence demonstrating that N. gonorrhoeae is capable of evading and
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actively suppressing the immune response to promote its survival in the host (reviewed
in [15]). These evasion and suppression mechanisms include sialylation of the gonococcal
LOS [16,17] and induction of anti-gonococcal Rmp (reduction-modifiable protein) antibod-
ies that block the bactericidal activity of IgG antibodies directed against gonococcal LOS or
porin protein [18]. In addition to non-protective humoral immune responses, N. gonorrhoeae
infection manipulates the adaptive cell-mediated response away from Th1/Th2-based
immunity and towards a Th17-driven neutrophilic inflammatory response by inducing
localized TGF-β and IL-10 cytokine production [19,20]. This immunologic bias toward
neutrophilic influx results in the cellular damage associated with serious clinical seque-
lae of gonorrhea and prevents the development of protective immunity ([21]; reviewed
recently in [8]).
In the absence of an effective vaccine and protective natural immunity against repeated
infection, public health control of gonorrhea has depended exclusively upon effective
and affordable antibiotic pharmacotherapy [15]. However, the continued resistance of
gonococcal strains to all antimicrobial drugs introduced as first-line treatment since the
1930s points to the possibility of widespread, untreatable N. gonorrhoeae infections in the
future. With N. gonorrhoeae assigned to ‘superbug’ status by the WHO, it is imperative that
novel antibiotics are developed and new potential targets for vaccine design are identified
in order to address the urgent need for prevention and treatment of gonorrhea. While
a number of reviews have been published on gonorrhea over the years, including some
that are recent [1,5,15], there is a current need for a scholarly focus on potential novel
therapeutics for the treatment of N. gonorrhoeae infection and on new approaches to antigen
target discovery for vaccine development. The aim of the current study, therefore, is to
review the evolution of chemotherapeutic treatment options for gonorrhea, discuss the
treatment potential of new therapeutics, and provide an update on the progress toward
the development of an anti-gonococcal vaccine, with a concentration on recent discoveries
related to vaccine antigen identification.
2. Methods
A literature search was conducted in November 2019 and updated in November 2020
using the PubMed, Scopus, clinicaltrials.gov, and Google Scholar databases. All avail-
able publications associated with anti-gonococcal therapeutics and vaccine development
were included. The literature search was conducted using the following search terms and
combinations thereof: “Neisseria gonorrhoeae”, “gonorrhea”, “drug treatments”, “vaccine”,
“vaccine development”, “novel drug or vaccine”, “future treatments”, “meningococcal
vaccine”, and “vaccine clinical trials”. All full-text articles including randomized controlled
trials (RCTs), meta-analyses, clinical trials, and systematic reviews were screened for inclu-
sion in this extensive review. Only primary studies conducted on new therapeutics and
vaccine development for gonorrhea were included for extensive review. Articles were ex-
cluded if they were published in languages other than English. The date of publication was
not restricted in our screening process. To circumvent bias, two reviewers independently
searched the literature and assessed the eligibility of each study for inclusion based on the
predefined criteria. Two additional reviewers oversaw the study selection process.
3. Results
Figure 1 summarizes the study selection process and the search results obtained. The
initial search yielded articles in excess of 50,000. After screening and excluding duplications,
40 articles were identified for extensive review.
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the mid-1930s. Temporal shifts in the epidemiology of antimicrobial resistance patterns 
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pies, including sulfonamides, penicillins, earlier-generation cephalosporins, tetracyclines, 
streptomycin, and fluoroquinolones [1,6,22]. Resistance to sulfonamides, the first treat-
ment regimen for gonorrhea in the antibiotic pipeline, developed due to mutations ac-
quired in the folP gene, which reduced the binding affinity of sulfonamide for its target, 
dihydropteroate synthase [1]. Introduced into clinical practice in the period 1943–1944, 
penicillin was used to effectively treat gonorrhea for decades until the emergence of re-
sistant strains possessing a plasmid-mediated β-lactamase, an enzyme that inactivates β-
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3.1. Historical and Current Antibiotic Regimens for Treating Gonorrhea
As a sexually transmitted infection with centuries of history and a human-specific
pathology, N. gonorrhoeae has been exposed to many of the existing antibiotics in the an-
timicrobial armamentarium, with the consequent development of resistance to a wide
range of chemotherapeutic drugs. Figure 2 illustrates the evolution of first-line antibiotic
regimens for treating uncomplicated gonorrhea since the introduction of sulfonamides in
the mid-1930s. Temporal shifts in the epidemiology of antimicrobial resistance patterns
for N. gonorrhoeae have significantly impacted treatment recommendations. Gonococcal
strains have emerged worldwide that are resistant to all previous empirical monothera-
pies, including sulfonamides, penicillins, earlier-generation cephalosporins, tetracyclines,
streptomycin, and fluoroquinolones [1,6,22]. Resistance to sulfonamides, the first treatment
regimen for gonorrhea in the antibiotic pipeline, developed due to mutations acquired
in the folP gene, which reduced the binding affinity of sulfonamide for its target, dihy-
dropteroate synthase [1]. Introduced into clinical practice in the period 1943–1944, penicillin
was used to effectively treat gonorrhea for decades until the emergence of resistant strains
possessing a plasmid-mediated β-lactamase, an enzyme that inactivates β-lactam antibi-
otics. Alternative antibiotics such as tetracycline were also effective in treating gonorrhea
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until the occurrence of resistant N. gonorrhoeae strains harboring the ribosomal protection
protein TetM which led to the discontinuation of tetracycline as a treatment option [1].
Overexpression of efflux pumps, reduced uptake, and modification of drug targets have
been identified as other mechanisms by which N. gonorrhoeae has developed resistance to
antibiotics in the treatment pipeline [23].
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ll i the introduction of fluoroquinolones as anti-gonoc ccal therapy, ci rofloxacin-
resistant N. go orrhoeae st ains merged as a esult of sel ction of genetic mutations in gyrA
and parC, which reduced drug binding to tar ets DNA gyrase and topoisomerase IV, respec-
tively [1]. Not surprisingly, flu roquinolo es were emoved from the CDC-recommended
guidelines in 2007 (Fi re 2), l avi g extended-spectrum cephalosporins as the last bulwark
in empiric anti-gonococcal mo otherapy. Third-generation cephalosporins (oral cefixime and
injectable ceftriax ne) were th treatment of choice until 2012 when a rising rate gonococcal
resistance prompted the CDC t recommend removing cefixime from trea ment regimens [6].
Emerging resistance and clinical tr at t failures associated with ceftriaxone use have al-
ready been documented in countries outside the US, highlighting the possible transmission
of untreatable onorrhea [24,25]. As of 2020, the CDC guidelines recommend combination
antibiotic therapy consisting f a si gle intramuscul r dose of ceftriaxone (250 mg) nd a
single oral dose of macrolide azithromycin (1 g) administered simultaneously as the first-line
empirical treat ent for unco plicated urogenital and anorectal gonococcal infections [6]. Of
serious concern, a gonococcal strain resistant to the currently recommended dual antimicrobial
therapy was recently isolated from a patient with pharyngeal gonorrhea, resulting in the
first recorded clinical failure of ceftriaxone and azithromycin [26]. Since then, clinical isolates
of N. gonorrhoeae exhibiting combined high-level resistance to azithromycin and resistance
to ceftriaxone have been documented as part of public health surveillance programs in the
United Kingdom and Australia [27]. It is therefore unlikely that dual antimicrobial regimens
will completely prevent resistance emergence among N. gonorrhoeae strains, requiring the
development of novel, affordable antibiotics for monotherapies or inclusion in new dual
treatment regimens [23]. The acquisition and spread of antimicrobial resistance determinants
among naturally competent gonococcal strains means that the antibiotic pipeline will need to
be replenished with new, efficacious drug therapies in order to meet the therapeutic challenge
of treating gonorrhea. However, bacterial drug targets are finite in number, and preventa-
tive vaccination is the optimal long-term approach to controlling gonococcal infection and
reducing disease burden.
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3.2. Vaccine Development: Clinical Trials, Human Challenge Trials, and Observational Human
Studies
Recorded efforts to develop a vaccine to protect against N. gonorrhoeae infection date
back to the early 1900s. Since that time, only four candidate gonococcal vaccines have
advanced to the stage of clinical trials or human challenge trials. Little information is
available on the first, now century-old, clinical evaluation of a gonococcal whole-cell
vaccine [28]. The second was a parenterally administered crude, heat-killed, partially
lysed whole-cell vaccine, which was evaluated via a double-blind placebo-controlled study
conducted in a population of 62 Inuit volunteers in northern Canada [29]. There was a
high incidence and prevalence of N. gonorrhoeae in this study population. Of the 33 subjects
vaccinated and the 24 subjects in the placebo group, 10 (30%) and 7 (24%), respectively,
contracted gonorrhea in the year following vaccination, resulting in no significant difference
between the control and experimental groups (p = 0.78) [29]. The third candidate vaccine
consisted of a single-antigen purified pilus that was examined in a double-blind placebo-
controlled trial involving the randomization of 3250 US military personnel in Korea [30].
The gonococcal pilus vaccine was delivered intradermally to volunteers using a two-dose
regimen separated by 14 days. The vaccine failed to protect male volunteers against
gonococcal urethritis, with 108 and 102 subjects from the vaccine and placebo groups,
respectively, acquiring gonorrhea 15 days or more after inoculation [30]. Both the killed
whole-cell and purified pilin vaccines failed to induce protection against heterologous
reinfection. Finally, a human vaccine challenge study involved parenterally immunizing
male subjects with purified gonococcal protein I, the major outer membrane porin protein
that constitutes a channel for the entry of small molecules through the outer membrane of N.
gonorrhoeae. The protein I-based vaccine elicited a significant antibody response in subjects
(similar to the pilus-based vaccine), but offered no protection against an intraurethral
challenge in men with the homologous gonococcal strain (reviewed in [31]). Beyond these
four candidate vaccines, no preclinical development of gonococcal vaccine targets has
progressed to human studies, underscoring the challenges and difficulties associated with
N. gonorrhoeae vaccine development. The primary obstacles include the lack of known
correlates of immune protection against natural mucosal infections and the high degree of
phase and antigenic variability of N. gonorrhoeae surface antigens (reviewed in [1]). The
failure of early clinical trials and vaccine studies was likely due, in part, to the fact that
antigenically variable gonococcal pilin and porin PorB proteins were targeted, resulting in
a lack of broadly protective antibody responses.
Recently, novel high-throughput approaches, such as proteomics-driven reverse vac-
cinology and in silico subtractive genomics (discussed in more detail in the following
sections), are being applied to the task of identifying new surface-expressed and antigeni-
cally conserved proteins in N. gonorrhoeae that could be explored as targets for vaccine
development. Other promising preclinical efforts have focused on the design of novel vac-
cine platforms, antigen delivery systems and adjuvants, including bacterial ‘ghosts’ (empty
bacterial cell envelopes) as potent carriers for the delivery of a PorB-based DNA vaccine [32]
and microneedle skin patches for transdermal delivery of formalin-fixed N. gonorrhoeae
whole cells [33]. In a study reported by Jiao et al. [32], a novel N. gonorrhoeae DNA vaccine
was constructed by inserting the full-length porB gene into the eukaryotic expression
vector pVAX1 and then the recombinant pVAX1-porB plasmid was loaded into Salmonella
enteritidis (SE) ghosts for delivery. Mice orally immunized with SE ghosts (+ pVAX1-porB)
elicited gonococcal PorB-specific serum antibodies that had bactericidal activity in contrast
to plasmid DNA alone, suggesting that the SE ghosts had a strong adjuvant effect on the
immunogenicity of the DNA vaccine. Moreover, SE ghosts (+ pVAX1-porB) promoted
dendritic cell maturation and induced a strong cellular immune response in immunized
mice, with increased levels of CD3+, CD4+, and CD8+ T cell subpopulations [32]. While
PorB-based DNA vaccines have not progressed beyond the preclinical evaluation stage,
the bacterial ‘ghost’ platform technology does offer a potential approach to enhancing the
immunogenicity of a N. gonorrhoeae vaccine target.
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The recent development of an effective vaccine against the closely related Neisseria
meningitidis serogroup B, combined with new tools for vaccine antigen mining, has raised
optimism that an efficacious N. gonorrhoeae vaccine may be possible in the near future.
While the infectious pathologies of these strictly human pathogens are distinct, N. gon-
orrhoeae and N. meningitidis exhibit 80–90% genomic identity at the nucleotide sequence
level, with many surface-exposed proteins sharing a high degree of sequence identity
(e.g., methionine sulfoxide reductase MsrA/B shares 98% amino acid identity) [34,35].
Studies employing epidemiological surveillance data suggest that outer membrane vesicle
(OMV) N. meningitidis group B vaccines reduce the incidence of gonorrhea (Table 1; [36,37]).
In a multiclinic retrospective case–control study, Petousis-Harris et al. [36] investigated
the association of immunization with a meningococcal group B OMV vaccine (trade name
MeNZB) and gonorrhea diagnosis. Vaccinated subjects were those individuals who had re-
ceived the serogroup B OMV vaccine MeNZB as part of a national immunization campaign
in New Zealand. Study results showed that MeNZB-immunized subjects were significantly
less likely to be diagnosed with gonorrhea over a 10 year period following vaccination
than unimmunized subjects [36]. After adjusting for potential confounding factors, the
effectiveness of the MeNZB vaccine against gonorrhea was estimated to be 31%. While
the estimated vaccine efficacy was modest, this was the first report of a vaccine providing
some degree of protective immunity against gonorrhea in humans. Similarly, another epi-
demiological study observed decreased rates of gonorrhea incidence in the general public
following mass vaccination with the meningococcal serogroup B vaccine VA-MENGOC-BC
in Cuba [37]. A recent investigation expanded on the New Zealand findings by demon-
strating that individuals immunized with the new four-component meningococcal group
B vaccine 4CMenB, trade name Bexsero® (GlaxoSmithKline), induced antibodies in hu-
mans that specifically recognized gonococcal proteins [38]. Bexsero® contains the antigen
components of MeNZB (meningococcal group B OMVs) in addition to three recombinant
meningococcal antigens (Neisseria adhesin A, NadA; factor H-binding protein, fHbp; Neis-
serial heparin-binding antigen, NHBA) (Table 1). Semchenko et al. [38] demonstrated that
anti-gonococcal antibodies generated as a result of Bexsero® immunization cross-reacted
with the highly conserved NHBA protein in N. gonorrhoeae, suggesting that Bexsero® may
provide additional protection above what has been observed for MeNZB. Collectively,
these studies suggest the potential utility of OMV meningococcal serogroup B vaccines in
eliciting a cross-protective effect against N. gonorrhoeae and may help to reduce the global
incidence of gonorrhea in the absence of a specific effective vaccine.
3.3. Current Status of Neisseria gonorrhoeae Antigens for Vaccine Development
Safe and effective vaccines against gonococcal infections are desperately needed to
contain the global emergence of multidrug-resistant N. gonorrhoeae strains. With currently
no new antibiotics for monotherapy in the drug pipeline, health care practitioners are left
to administer aggressive and invasive dual therapy regimens to treat gonorrhea. However,
the ability of gonococci to rapidly acquire drug resistance suggests that even newly devel-
oped, novel antibiotics would eventually become ineffective. Development of an effective
anti-gonococcal vaccine is, therefore, the only sustainable approach to controlling the pro-
liferation of N. gonorrhoeae infections [39]. The identification of vaccine antigens is critical
to this endeavor, and anti-gonococcal vaccine development continues to remain largely in
the antigen discovery phase. Ideally, such vaccine antigens should be highly conserved
and broadly distributed among diverse gonococcal strains, immunogenic, and capable of
eliciting bactericidal or opsonic antibodies or antibodies that block essential physiological
functions of N. gonorrhoeae. In contrast to the closely related Neisseria meningitidis, N. gonor-
rhoeae does not express a surface capsule, which constitutes a potent immunogenic target in
several FDA-approved meningococcal vaccines (e.g., Menomune, Menactra, and Menveo).
As a result, gonococcal vaccine research has focused on proteinaceous targets such as outer
membrane proteins and surface-accessible lipoproteins.
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As presented in Table 1, numerous gonococcal surface-exposed structures capable
of inducing bactericidal antibodies in immunized animals have been identified and pro-
posed as potential vaccine candidates. The vast majority of these vaccine targets play
critical roles in various physiologic functions of the pathogen and include adherence and
invasion of mucosal epithelial cells [40–45], iron acquisition [46], immune evasion due
to serum complement resistance [47,48] and efflux of neutrophil-derived antimicrobial
peptides [49,50], cellular metabolism [51], and oxidative stress protection [35]. By contrast,
one novel study focused on the presence of filamentous NgoΦfil bacteriophage (phage)
DNA in gonococcal genomes as a potential source for vaccine candidates (Table 1). Phage
proteins displayed on the surface of N. gonorrhoeae cells were shown to elicit bactericidal
antibodies in rabbits, and anti-NgoΦfil protein antibodies blocked gonococcal adherence
to human endocervical cells [52].
Gonococcal adhesion to human mucosal epithelium constitutes the primary event
in the establishment of N. gonorrhoeae infection (reviewed in [53]), and consequently, vac-
cine development efforts have concentrated on the utility of Type IV pili, opacity (Opa)
proteins, and major porin protein PorB as vaccine targets (Table 1). Initial attachment
of N. gonorrhoeae to the epithelial cell surface and subsequent colonization is mediated
largely by Type IV pili. Adhesins such as the outer membrane Opa proteins facilitate more
intimate interactions of N. gonorrhoeae with carcinoembryonic antigen-related cell adhesion
molecule (CEACAM) receptors on epithelial cells [41,54]. Type IV pili and Opa proteins are
expressed during natural infection and are essential factors in the ability of gonococci to
colonize the genital tract epithelium (reviewed in [53]). PorB is the most abundant protein
in the gonococcal outer membrane and influences bacterial colonization and invasion,
as well as contributing to serum complement resistance ([42]; reviewed in [15]). At first
glance, these gonococcal antigens—pilin, Opa, and PorB—appear to be ideal targets for a
vaccine because of their surface accessibility and essential roles in the critical first step in
N. gonorrhoeae pathogenesis. These gonococcal surface antigens, however, are subjected
to genetic inter- and intravariability. In the case of Type IV pili, for instance, intrachro-
mosomal recombination events at the expression locus of the major pilus subunit create
antigenically distinct pilin variants (reviewed in [15]). Additionally, opa genes undergo
phase variation in which their expression in the gonococcus is reversibly turned on or
off, making these surface antigens challenging as vaccine targets. Targeting the relatively
conserved semi-variable (SV) loop of mature Opa proteins with cyclic peptides, however,
has shown some potential in stimulating a humoral response that recognizes a wide range
of antigenically distinct Opa variants [44].
Other gonococcal antigens have been identified as inducing a functional antibody
response in laboratory animals and are characterized by antigenic conservation and stable
expression between N. gonorrhoeae strains and within the same strain, attracting research
interest in their possible utility as vaccine targets. These potential vaccine candidates most
notably include transferrin-binding proteins A and B [46]; MtrE of the MtrCDE multidrug
transporter system [49,50]; nitrite reductase AniA [51]; methionine sulfoxide reductase
MsrA/B [35]; and neisserial surface protein A (NspA) [47,48] (Table 1). MtrE and NspA
are stably expressed proteins with surface-exposed epitopes that are highly conserved
at the sequence level among gonococcal strains; both proteins contribute to the ability
of N. gonorrhoeae to evade host innate immune defenses [48,49]. In addition, MtrCDE
was previously shown to be essential for the in vivo biological fitness of N. gonorrhoeae in
a murine vaginal tract infection model [55,56] and is upregulated in antibiotic-resistant
N. gonorrhoeae strains, resulting in elevated minimal inhibitory concentrations (MICs) of
antibiotics [57]. Studies demonstrated that mice immunized with the surface-expressed
Loop 2 of MtrE and a recombinant plasmid encoding gonococcal NspA generated target-
specific antibody titers that displayed bactericidal activity [47,50]. Both MtrE and NspA
meet the criteria for a successful vaccine antigen.
In the absence of an effective FDA-approved prophylactic against N. gonorrhoeae
infections, new strategies are needed to expand the pool of candidates considered for
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potential clinical vaccine development. One innovative approach is reverse vaccinology
antigen mining using a combination of high-throughput quantitative proteomics and
bioinformatics (recently reviewed in [58]). The utility of proteomic technology has been
clearly demonstrated in the discovery of N. gonorrhoeae lipoprotein MetQ (NGO2139).
Initially, this functionally uncharacterized protein (NGO2139) was identified as a result of
high-throughput proteomic profiling of N. gonorrhoeae strain FA1090 grown under three
environmental conditions mimicking in vivo microecological niches in the human host:
(i) exposure to normal human serum, (ii) iron limitation, and (iii) oxygen deprivation
(i.e., anaerobiosis) [59]. NGO2139 was discovered as part of a proteome subset of ubiqui-
tous proteins whose expression remained unchanged upon exposure of N. gonorrhoeae to
normal human serum, iron depletion, and anaerobic conditions. Rabbit anti-NGO2139
antibodies exhibited bactericidal activity and cross-reacted against diverse gonococcal
isolates [59]. Bioinformatics revealed that NGO2139 contains a classical lipoprotein signal
peptide indicative of outer membrane-localized proteins [59]. A subsequent investigation
verified the functional role of NGO2139 as the L-methionine-binding component, MetQ, of
an ABC transporter system and showed that MetQ is involved in gonococcal adherence
to cervical epithelial cells [60]. Semchenko and colleagues [60] demonstrated that mouse
anti-MetQ polyclonal antibodies were not only bactericidal, but also reduced adherence
of N. gonorrhoeae to cervical epithelial cells. Furthermore, MetQ is widely distributed.
Homologs of this proteomics-derived vaccine candidate are present in all 14 N. gonorrhoeae
reference strains comprising the 2016 WHO panel, as well as in 3 examined Neisseria menin-
gitidis strains [39]. Most recently, a preclinical assessment of MetQ was conducted using
a female mouse model of genital tract infection. Sikora et al. [61] created a recombinant
protein construct with the most phylogenetically prevalent allele of MetQ (rMetQ) and
formulated rMetQ with the adjuvant CpG. Mice were immunized with rMetQ-CpG by
subcutaneous injection, followed by three intranasal boosts, and subsequently challenged
with N. gonorrhoeae. Mice immunized with rMetQ-CpG cleared the experimental infection
significantly faster than control mice, prompting researchers to propose the inclusion of
MetQ in a broad-spectrum subunit vaccine for gonorrhea [61]. Other proteomics-derived
vaccine candidates should be prioritized for preclinical evaluation based on the criteria of
conservation, function in N. gonorrhoeae pathogenesis, and immunogenicity.
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Table 1. Potential Antigen Targets for Gonorrhea Vaccine and Drug Development.
Target Study Design Functional Role Immunogenic Effect or DrugBinding Potential Candidate Antigen Attributes References
Adherence and Invasion of Mucosal Epithelial Cells
Porin (PorB) In vitro cell-based studies
• Outer membrane
protein
• Contributes to host cell
invasion and serum
complement resistance







Type IV pilin In vitro cell-based studies,immunization
• Outer membrane
protein




gonococcal pilin sequences blocked
GC adhesion
Phase and antigenically variable [40]
Opacity associated (Opa)
protein










invasion of host cells
Bactericidal antibodies generated







in vitro cell-based studies
• Critical for initial







blocked pilin glycan–CR3 I-domain
interaction (host-targeted therapy)
Increased efficacy compared to












Conserved Tbp epitopes [46]
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Table 1. Cont.
Target Study Design Functional Role Immunogenic Effect or DrugBinding Potential Candidate Antigen Attributes References
Immune Evasion and Virulence
MtrE In vitro cell-based studies
• Outer membrane
channel of the multiple
transferable resistance
(Mtr) system (MtrCDE)
• Contributes to survival




Elicited bactericidal antibodies Highly conserved, surface exposed [49,50]








Elicited NspA-specific IgG and IgA
antibodies with bactericidal and
opsonic activities
Highly conserved, surface exposed [47,48]
Peptide mimic of glycan
epitope (2C7) of GC LOS





• Increases survival of GC
in humans and
mouse model
• Mice immunized with
multi-antigenic peptide






Peptide mimic of glycan
epitope (2C7) of GC LOS
Preclinical experimental
infection model
• Peptide mimic of
2C7 epitope
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Table 1. Cont.
Target Study Design Functional Role Immunogenic Effect or DrugBinding Potential Candidate Antigen Attributes References
Vaccine/Drug Antigens Identified by In Silico and Proteomic Approaches





• Involved in L-Lysine
biosynthesis








• Possible role in
threonine biosynthesis
and pilin antigenicity
• Present in all gonococcal
strains examined and
part of the gonococcal
core genome
Anti-NGO0690 antibodies
bactericidal against all 4 diverse
gonococcal strains tested (low
bactericidal titers)
Largely conserved with a small
range of allelic variability [68]
NGO0948 Reverse vaccinology,bioinformatics
• P/OM lipoprotein of the
NlpB family




• Present in all gonococcal
strains examined and
part of the gonococcal
core genome
Anti-NGO0948 antibodies
bactericidal against all 4 diverse
gonococcal strains tested (low
bactericidal titers)
Largely conserved with a small







• Present in all gonococcal
strains examined and




activity against 3/4 diverse
gonococcal strains tested
Largely conserved with a small
range of allelic variability [68]
Medicines 2021, 8, 11 13 of 22
Table 1. Cont.






• Present in all gonococcal
strains examined and
part of the gonococcal
core genome
Anti-NGO1701 antibodies
bactericidal against all 4 diverse
gonococcal strains tested (low
bactericidal titers)
Largely conserved with a small
range of allelic variability [68]
LptD (NGO1715) Proteomics-driven reversevaccinology
• Involved in LOS
assembly Elicited bactericidal antibodies Highly conserved, surface exposed [59]
BamA (NGO1801) Proteomics-driven reversevaccinology
• Involved in binding and
inserting beta-barrel
proteins into the OM
Elicited bactericidal antibodies Highly conserved, surface exposed [59]
TamA (NGO1956) Proteomics-driven reversevaccinology
• Involved in







• Involved in methionine
transport
Elicited bactericidal antibodies
MetQ formulated with CpG
(rMetQ-CpG) accelerated GC
clearance from challenged mice
and induced a protective immune
response in mice
Highly conserved, surface exposed [39,59,61]
NGO2054 Proteomics-driven reversevaccinology
• Hypothetical protein
• Predicted signal peptide
suggests OM
localization
Elicited bactericidal antibodies Highly conserved, surface exposed [59]
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Table 1. Cont.







profiling of WHO reference














Conserved, localized to cell
envelope or outer membrane
fraction
[39]
Metabolism and Oxidative Stress Protection
AniA Mice, in vitro cell-basedstudies
• Copper-containing OM
nitrite reductase
• Catalyzes the reduction
of nitrite to nitric oxide
• Essential for growth and
survival of GC under
oxygen-limiting
conditions
Antibodies block nitrite reductase
function in a whole-cell assay Conserved, surface exposed [51]










killing of GC; capable of functional
blocking of MsrA/B activity




Rabbits, in vitro cell-based
studies
• NgoΦ6 filamentous
phage genes in GC
• Encode proteins needed
for progeny phage
production
Anti-phage IgG and IgA bound to
surface of GC cells; sera exhibited
bactericidal activity and blocked
GC adherence to cervical
epithelial cells
Phage genes present in all
sequenced GC strains; phage
proteins are surface exposed
[52]
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Table 1. Cont.



















Induced antigen-specific IgG and
antigen-specific adaptive cellular
immunity (CD4 and CD8
lymphocytes) in mice








• Used to control
meningococcal epidemic
in New Zealand
• >1 million people
vaccinated between
2004 and 2008
Associated with decreased rates of
gonorrhea; vaccinated individuals
were less likely to contract
gonorrhea than unvaccinated
controls
High genome identity between














High genome identity between
MEN and GC [37]




rabbit sera, human sera






induced by MeNZB OMV; strong
immune reactivity of anti-NHBA
antibodies to GC
Diverse GC strains contain NHBA
homolog; surface exposed [38]
† 2016 World Health Organization (WHO) reference panel consists of 14 diverse Neisseria gonorrhoeae strains. Abbreviations: LOS = lipooligosaccharide; GC = gonococcus (Neisseria gonorrhoeae);
MEN = meningococcus (Neisseria meningitidis); P/OM = periplasmic/outer membrane; NadA = Neisseria adhesin A protein; fHbp = factor H-binding protein; NHBA = Neisserial heparin-binding anti-
gen; ND = not determined.
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3.4. Repurposed Drugs, Novel Drug Targets for Gonorrhea Treatment, and Nanomaterials as
Drug Adjuvants
In light of the rapidly dwindling antibiotic options for multidrug-resistant N. gon-
orrhoeae infections, novel therapeutics or repurposed indications for existing drugs used
for other diseases are needed for clinical intervention. Repurposing existing drugs has
the distinct benefit of more rapidly achieving a solution to the clinical intervention chal-
lenge. As discussed earlier in this review, Type IV pili are critical for the adherence of
N. gonorrhoeae to epithelial cells. Previous studies have shown that gonococci initially
interact with complement receptor 3 (CR3) on the surface of the human cervical epithe-
lium via pilin-linked glycan with a terminal galactose [69,70]. The I-domain of CR3 binds
the terminal galactose of pilin glycan with high affinity [62,69]. Poole et al. [62] recently
mapped the galactose-binding epitope of the CR3 I-domain and showed that a peptide
mimic of this region competitively inhibited interaction between N. gonorrhoeae and CR3.
Screening of a compound library identified two drugs, carbamazepine and methyldopa,
currently approved for other clinical indications that were able to bind to the I-domain
and block pilin-CR3 interaction (Table 1; [62]). Both drugs, which are orally bioavailable,
were found to be more effective than ceftriaxone in curing an infection of primary human
cervical cells caused by multidrug-resistant gonococcal strains. Carbamazepine is a drug
currently used in the context of epilepsy and nerve pain, while methyldopa is an antihyper-
tensive drug of the alpha-2-agonist class. Poole and colleagues [62] found that the killing
of gonococci after a 24 h period of treatment with carbamazepine (≥10 µM) or methyldopa
(≥10 µM) was host cell-dependent, as these drugs did not affect gonococcal viability in
the absence of cervical epithelial cells. In addition, curing of the cervical infection ex vivo
occurred at dose amounts of carbamazepine and methyldopa that were lower than what
is currently approved for their respective indications [62]. In the absence of an effective
vaccine, potential host-targeted therapies, such as the one described by Poole et al. [62], will
need to be explored as alternative treatment modalities for multidrug-resistant gonorrhea.
Such host-targeted therapeutics are likely to be more recalcitrant to the development of
pathogen resistance.
The process of vaccine antigen identification has been revolutionized by high-throughput,
systems-based technologies combined with advanced computational tools. Bioinformatics
and omics technologies have expedited the target discovery phase of drug development by
eliminating time-consuming trial-and-error experimentation and prioritizing the theoretically
most promising candidate drug targets for in-depth laboratory testing. One such omics-based
approach is subtractive genomics in which species-specific novel therapeutic targets are
identified in silico by subtracting strain-specific paralogous and host-specific homologous
sequences from the bacterial proteome, leaving pathogen-specific core genes essential to
such crucial cellular functions as energy metabolism and amino acid biosynthesis. This
approach has been used to identify potential drug and vaccine targets in N. gonorrhoeae [67,71].
Most recently, Tanwer et al. [67] employed in silico subtractive genomics, combined with
molecular docking analyses, to identify 29 proteins essential to gonococcal survival and
propagation, including a cytosolic succinyltransferase (DapD) with a predicted function in
L-lysine biosynthesis (Table 1). Codon adaptation indexes (CAIs) were calculated for neisserial
gene sequences to predict essential genes in the N. gonorrhoeae genome (sequences with a
CAI > 0.75 were further examined). Applying molecular docking analyses, a novel lead
compound, ZINC06311339 (C18H22N6S3), was predicted to bind to the active site of DapD
through simulated protein-ligand interaction [67]. Although experimental verification is
required, such studies can facilitate the prioritization of novel therapeutic targets in the drug
development process. Additionally, the structure of essential bacterial proteins identified via
in silico strategies may be targeted using peptide-based drugs, which typically have high
specificity and low toxicity [72]. In one study, researchers developed an ‘antibiotic peptide’
that targeted and disrupted the folded structure of gonococcal methionine aminopeptidase,
an essential protein required for protein maturation [73]. This potential structure-disrupting
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peptide antibiotic was shown to inhibit gonococcal growth and infections in a human cervical
epithelial cell model.
Due to the reduction in treatment options for gonorrhea, alternative antimicrobial ther-
apies are urgently needed to address the widespread dissemination of multidrug-resistant
N. gonorrhoeae. To date, the application of nanotechnology and nanomaterials has received
very little attention as a potential clinical intervention for gonococcal infection. In the
first reported study investigating the antibacterial activities of nanomaterials against N.
gonorrhoeae, Li et al. [74] found that silver nanoparticles (Ag NPs, 120 nm in diameter)
exhibited the most potent antimicrobial activity against an ATCC strain of N. gonorrhoeae,
characterized by reduced colony formation, damaged cell membranes, and decreased gono-
coccal viability by approximately 35% compared to the control group [74]. Furthermore,
the 120 nm Ag NPs were not cytotoxic to human epithelial and fibroblast cell lines. Most
significant, the combination of Ag NPs (120 nm) and cefmetazole (ineffective by itself)
appeared to exert an ‘additive’ antimicrobial effect against clinical multidrug-resistant
isolates of N. gonorrhoeae, with cefmetazole MICs for all tested multidrug-resistant isolates
declining to below the sensitivity threshold when this antibiotic was combined with Ag
NPs [74]. Additional research is clearly needed to determine whether Ag NPs act by dis-
rupting cell membrane integrity and permeability and/or by complexing with cefmetazole
to deliver a greater antibiotic dose to the pathogen. The toxicity of Ag NPs also needs to be
assessed carefully. Nonetheless, the possibility that Ag NPs or other nanomaterials could
be used as an adjuvant to bolster the anti-gonococcal activity of currently ineffective antibi-
otics, such as cefmetazole, against multidrug-resistant isolates is intriguing and should be
explored further. Other investigations have focused on the selective delivery and stability
of broad-spectrum silver-based microbicides in seminal fluid and their bactericidal activity
against N. gonorrhoeae [75].
4. Discussion
Gonorrhea remains a challenging disease with wide-ranging clinical and social effects.
For over 80 years, treatment of gonorrhea has evolved through changing antibiotic regi-
mens as a result of N. gonorrhoeae resistance. Antibiotics such as penicillin, tetracyclines,
quinolones, and macrolides, which previously were effective against N. gonorrhoeae, are no
longer recommended as the first-line monotherapy due to widespread resistance among
gonococci. Resistance to current extended-spectrum cephalosporin-based treatments has
already emerged [76,77]. While antibiotic combinations will continue to offer limited op-
tions for gonorrhea treatment, there are currently no pipeline drugs in development to
control multidrug-resistant N. gonorrhoeae infections. Although research may yield new
therapeutic options, the genetic plasticity of the pathogen, coupled with its proficiency at
acquiring genes encoding resistance determinants from the environment, will likely make
the effectiveness of any new antibiotic short-lived.
It is therefore important that any long-term strategy designed to address the global
burden of gonorrhea include vaccination. In a model-based epidemiological simulation
study of vaccine efficacy, it was estimated that a 90% reduction in gonorrhea prevalence
could be achieved in 20 years if a non-waning gonococcal vaccine of 50% effectiveness (or
a 100% efficacy vaccine that wanes after 7.5 years) is administered to all 13 year olds [78].
There is currently no approved vaccine for protection against gonorrhea, and no candidate
vaccine targets are at any advanced stage of clinical development. Potential gonorrhea
vaccines have not progressed beyond the stages of discovery and preclinical evaluation
to identify immune correlates and understand surrogates of protection. While there is a
preponderance of scientific publications on gonorrhea, there is not much on vaccines. This
can be attributed to historical failures at developing gonococcal vaccines.
A number of major challenges have been identified as limiting the successful develop-
ment of vaccines against gonorrhea. One primary obstacle is that the infective mechanism
and mode of drug resistance for this pathogen are not completely understood. Similarly,
gonococcal mechanisms of host immune protection have not been clearly elucidated. An-
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other challenge is that natural infection of N. gonorrhoeae does not confer immunity, nor
does it protect against reinfection. Due to the ability of N. gonorrhoeae to suppress and
divert host immune responses, only a transient and weak mucosal immune response is
associated with gonorrheal infections. Most vaccine development is based on the principle
of replicating the immunity of natural infection. Thus, conventional approaches such as
the use of live-attenuated or inactivated N. gonorrhoeae will not be effective for gonococcal
vaccination. Despite these limitations, the successful development of vaccines against
human papilloma virus (HPV, the most common sexually transmitted infection), the de-
velopment of vaccine technologies that employ antigen engineering, immune response
optimization efforts, and enhanced targeted vaccine delivery have engendered optimism
that development of a vaccine against N. gonorrhoeae is possible. Using the protein-based
meningococcal vaccine as a prototype, for example, most vaccine optimists believe that an
effective gonococcal vaccine can be developed. Other challenges to vaccine development
include the observation that several strains of infective N. gonorrhoeae possess notable
differences in their pathogenic behavior [24]. This heterogeneity implies the possibility
of variation in the immune response depending on the strain and its associated virulence.
Finally, perhaps the most relevant challenge to clinical vaccine development is the fact that
N. gonorrhoeae is an obligate human pathogen, with the consequent absence of reliable test
models for infection studies. The human-specific pathogenicity of N. gonorrhoeae renders
typical animal models as poor estimations at best. Although animal models are still useful,
they must be complemented with studies in human cells or clinical infections in order
to produce meaningful data. Thus far, only female mice treated with 17-β estradiol have
been reliably used as a small-animal model of lower genital tract infection [79,80]. Studies
in this mice model have shown major reduction in the load and duration of gonococcal
colonization with intraperitoneal administration of a multiantigenic peptide (MAP1) (a
peptide mimic and an immunologic surrogate of the 2C7-OS epitope) [65], subcutaneously
administered (and footpad-boosted) recombinant refolded porin delivered by virus repli-
cation particles (rrPorB-VRP) [81], and the nasally administered outer membrane vesicle
(OMV) vaccine [82].
In the past 50 years, only three candidate gonococcal vaccines have progressed to
clinical trials, with none offering reliable protection [29–31]. The experience and lessons
learned from these trials suggest that a successful vaccine will need to be multivariate—
capable of targeting multiple conserved epitopes. Moving forward, both new therapeutics
and vaccines will need to be developed to keep pace with an evolving pathogen. There
are only limited potential drug targets in N. gonorrhoeae, and the rate at which gonococci
acquire resistance to existing drugs is cause for concern. Focusing on the non-variable
host cell structures contacted by gonococci during adherence, colonization, and invasion
may be a plausible approach for the development of new therapeutics. The success of
maraviroc [83], an anti-attachment retroviral drug that targets host immune cells, may be
a template in this regard. Other therapeutic options, including immunomodulators and
monoclonal antibodies to enhance host immunity, may also be avenues of exploration for
drug discovery scientists.
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